https://www.selleckchem.com/products/gw788388.html
1; 95% CI 1.2-3.6; p= 0.007). Addition of belimumab to ST independently protected against adverse SF-36 general health (OR 0.8; 95% CI 0.6-1.0; p= 0.025) and FACIT-F 30 (OR 0.8; 95% CI 0.6-1.0; p= 0.018). Overweight and obesity contributed to adverse physical and mental HRQoL outcomes after therapeutic intervention in SLE patients, and underweight contributed to adverse mental HRQoL outcome. A protective effect of belimumab against adverse general health and severe fatigue was implicated. Overweight and obesity contributed to adve
Like
Comment
Share
